Get the Stockscreener App
2.055
3.54%
-0.075
Nrx Pharmaceuticals Inc stock is traded at $2.055, with a volume of 100.06K.
It is down -3.54% in the last 24 hours and down -30.12% over the past month.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.
See More
Previous Close:
$2.13
Open:
$2.1743
24h Volume:
100.06K
Relative Volume:
0.09
Market Cap:
$34.85M
Revenue:
-
Net Income/Loss:
$-30.15M
P/E Ratio:
-0.5138
EPS:
-4
Net Cash Flow:
$-21.66M
1W Performance:
-4.88%
1M Performance:
-30.12%
6M Performance:
+19.45%
1Y Performance:
-55.63%
1-Day Range:
$1.98
$2.18
1-Week Range:
$1.95
$2.205
52-Week Range:
$1.10
$6.01
Nrx Pharmaceuticals Inc Stock (NRXP) Company Profile
Name
Nrx Pharmaceuticals Inc
Sector
Industry
Phone
484-254-6134
Address
1201 ORANGE STREET, WILMINGTON
Compare NRXP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NRXP
Nrx Pharmaceuticals Inc
|
2.055 | 34.85M | 0 | -30.15M | -21.66M | -4.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
501.62 | 130.96B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
682.34 | 75.53B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
580.86 | 35.07B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.32 | 31.72B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
252.35 | 26.76B | 3.32B | -860.46M | -1.04B | -8.32 |
Nrx Pharmaceuticals Inc Stock (NRXP) Latest News
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) to Report Fourth Quarter and Full Year 2024 Financial Results and Provide a Corporate Update on March 17, 2025 - BioSpace
NRx Pharmaceuticals Readies Major Financial Update: Full Year Results and Strategic Outlook Coming March 17 - StockTitan
NRx Pharmaceuticals to Post Q4 Earnings: How to Play the Stock? - MSN
NRx Pharmaceuticals, Inc. (NRXP): Among the Best Psychedelic Stocks to Buy in 2025 - Insider Monkey
Relief Therapeutics Reports that its Collaboration Partner, NRx Pharmaceuticals, has Submitted an Application for Emergency Use Authorization for Aviptadil to the U.S. Food & Drug Administration - ACCESS Newswire
NRx Pharmaceuticals (NASDAQ:NRXP) Trading Up 4.4% – Time to Buy? - Defense World
Relief Therapeutics Reports that Collaboration Partner, NRx Pharmaceuticals, has Announced Additional Results from the Aviptadil U.S. Expanded Access Protocol for Patients with Critical COVID-19 - ACCESS Newswire
NRx Pharmaceuticals regains Nasdaq compliance - MSN
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Advances Relationship with Anson Funds with $8.9 Million Financing, Including Above the Market Equity and Senior Secured Debt - br.ADVFN.com
HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) Announce Signing of a Letter of Intent to Acquire its First Florida Interventional Psychiatry Clinics - br.ADVFN.com
HOPE Therapeutics™, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Conduct Investor Workshop at the Mar-A-Lago Club - br.ADVFN.com
HOPE Therapeutics™, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Engage BTIG as Financial Advisor - br.ADVFN.com
NRx Pharmaceuticals (NASDAQ:NRXP) Appoints Michael Abrams as Chief Financial Officer - br.ADVFN.com
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reschedules Conference Call to Discuss Third Quarter and Year to Date 2024 Financial Results to November 18, 2024 - br.ADVFN.com
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) and HOPE Therapeutics™, Inc. to Present at the Oppenheimer 35th Annual Healthcare Conference on February 12, 2025 - Finansavisen
Major Biotech Conferences Alert: NRx Pharmaceuticals Sets Stage for Key Industry Updates - StockTitan
HOPE Therapeutics and NRx Pharmaceuticals Engage BTIG as Financial Advisor - citybiz
NRx Pharmaceuticals, Inc. announced that it expects to receive $1.999998 million in funding from JGS Holdings LLC - Marketscreener.com
HOPE Therapeutics™, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:N - GuruFocus.com
HOPE Therapeutics and NRx Pharmaceuticals Execute Agreement for $27 Million Funding Transaction for HOPE Clinic Acquisition - citybiz
Small-Cap NRx Pharma’s Stock Draws Heavy Retail Buzz After Securing $27M Funding - NewsBreak
SEC Form 424B3 filed by NRX Pharmaceuticals Inc. - Quantisnow
NRx secures $27 million for mental health clinic expansion By Investing.com - Investing.com South Africa
S&P 500 ESG (ESG) QuotePress Release - The Globe and Mail
TSX Composite Index (TXCX) QuotePress Release - The Globe and Mail
Biotech Soars On Large Investment Announcement Into Its Subsidiary - The Globe and Mail
TSX 60 Shariah Index (TXSI) QuotePress Release - The Globe and Mail
NRX Pharmaceuticals Unit Secures $27 Million Funding; Shares Jump -January 28, 2025 at 02:50 pm EST - Marketscreener.com
What's Going On With NRX Pharmaceuticals Stock Tuesday?NRX Pharmaceuticals (NASDAQ:NRXP) - Benzinga
NRx secures $27 million for mental health clinic expansion - Investing.com
NRx Pharmaceuticals announces $3.5M registered direct offering - TipRanks
HOPE Therapeutics™, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Execute Agreement for $27 Million Funding Transaction for HOPE Clinic Acquisition - StreetInsider.com
NRx Pharma's $8.9M Deal Unlocks Path to FDA Approval for Revolutionary Depression Treatments - StockTitan
Transforming Mental Health Treatments and Expanding Clinic Networks: NRx Pharmaceuticals, Inc. (Stock Symbol: NRXP) - The Globe and Mail
Transforming Mental Health Treatments and Expanding Clinic - openPR
NRx Pharmaceuticals Regains Compliance With Nasdaq Minimum Market Value - citybiz
NRX Pharmaceuticals Board Changes and Nasdaq Compliance - TipRanks
NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Regains Compliance With - GuruFocus.com
NRx Pharmaceuticals Regains Nasdaq Compliance, Confirms Listing Security - StockTitan
NRx Pharmaceuticals Advances Towards FDA Approval with Key Stability Milestone for NRX-100 - MSN
NRx Pharma unit to acquire psychiatric facility Kadima - MSN
NRx Pharmaceuticals Appoints Michael Taylor To Board - citybiz
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces the Appointment of Michael Taylor to its Board of Directors and Appointment of Anita Nunes as Board Observer; Ms. Nunes to be Appointed Director of HOPE Therapeutics, Inc. - Quantisnow
NRx Pharmaceuticals Strengthens Board with Key Financial and Healthcare Veterans After $27M Deal - StockTitan
Nrx Pharmaceuticals Inc Stock (NRXP) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.68%
0.28%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):